<DOC>
	<DOCNO>NCT00290745</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen letrozole may fight breast cancer block use estrogen tumor cell lower amount estrogen body make . PURPOSE : This clinical trial study well tamoxifen letrozole work treat woman ductal carcinoma situ .</brief_summary>
	<brief_title>Tamoxifen Letrozole Treating Women With Ductal Carcinoma Situ</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response woman estrogen receptor-positive ductal carcinoma situ ( DCIS ) treat neoadjuvant hormonal therapy comprise tamoxifen letrozole , evaluate maximal change tumor diameter mammography MRI follow treatment . - Identify cellular antigen alter hormonal therapy . - Determine cellular antigen predictive clinical response hormonal therapy . - Evaluate whether genomic change gene expression DCIS alter hormonal therapy find candidate gene correlate response treatment . OUTLINE : This pilot study . Patients premenopausal receive oral tamoxifen daily 3 month absence unacceptable toxicity . Patients post menopausal receive oral letrozole daily 3 month absence unacceptable toxicity . After 3 month hormonal therapy , patient undergo lumpectomy mastectomy . After completion study treatment , patient follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ductal carcinoma situ ( DCIS ) core biopsy No evidence contralateral breast disease palpable mass breast examination No presence suspicion invasive cancer , include contralateral invasive cancer , core biopsy MRI No document ipsilateral axillary adenopathy Planning undergo lumpectomy mastectomy Estrogen receptor ( ER ) positive tumor immunohistochemistry PATIENT CHARACTERISTICS : Female patient Premenopausal postmenopausal Postmenopausal define follow : No spontaneous menses ≥ 1 year Bilateral oophorectomy Radiation castration amenorrheic ≥ 3 month Folliclestimulating hormone ( FSH ) &gt; 20 IU/L AND hormonal therapy ( e.g. , hormone replacement therapy birth control pill ) ≥ 1 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No comorbidities contraindicate use tamoxifen , include following : Prior history thrombotic event History hypercoagulable state History endometrial hyperplasia Abnormal vaginal bleeding No history contrast dyerelated allergies/reactions No history metalcontaining prosthesis implant PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>